Cargando…

Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE

Patients treated with edoxaban may require diagnostic and therapeutic procedures that involve edoxaban interruption. Although heparin bridging strategies are not recommended, heparin is frequently used in clinical practice. However, whether heparin use decreases thromboembolic risk remains unclear,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santamaria, Amparo, Chen, Cathy, Colonna, Paolo, von Heymann, Christian, Saxena, Manish, Vanassche, Thomas, Jin, James, Unverdorben, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498703/ https://www.ncbi.nlm.nih.gov/pubmed/37697813 http://dx.doi.org/10.1177/10760296231200223

Ejemplares similares

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
por: Chen, Cathy, et al.
Publicado: (2023)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study
por: Colonna, Paolo, et al.
Publicado: (2020)

Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study
por: Unverdorben, M., et al.
Publicado: (2020)

Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study
por: Unverdorben, M., et al.
Publicado: (2021)

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation
por: Olivera, Pável, et al.
Publicado: (2023)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study
por: Medina, Andria, et al.
Publicado: (2017)

Analysis of Readmissions Due to VTE—Using Hospital Data to Improve VTE Prophylaxis Compliance: A Quality Improvement Project
por: Hussain, Muzamil Hamid, et al.
Publicado: (2023)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
por: Chao, Tze-Fan, et al.
Publicado: (2023)

Use of Edoxaban for the Treatment of Heparin-Induced Thrombocytopenia
por: Kanamoto, Ryo, et al.
Publicado: (2020)

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE
por: Schapkaitz, E., et al.
Publicado: (2023)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya
por: Njuguna, Dennis, et al.
Publicado: (2023)

Establishment and Validation of a Postoperative VTE Prediction Model in Patients with Colorectal Cancer Undergoing Radical Resection: CRSPOT Nomogram
por: Wu, Yanan, et al.
Publicado: (2023)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin
por: Olson, Guy, et al.
Publicado: (2023)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
por: De Caterina, Raffaele, et al.
Publicado: (2021)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study
por: de Vries, T. A. C., et al.
Publicado: (2021)

Patients’ Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
por: Harenberg, Job, et al.
Publicado: (2022)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

The Social Bridging Project: Intergenerational Phone-Based Connections With Older Adults During the COVID-19 Pandemic
por: Noble, Louise W., et al.
Publicado: (2022)

Is There a “Blind Spot” in Point-of-Care Testing for Residual Heparin After Cardiopulmonary Bypass? A Prospective, Observational Cohort Study
por: Wand, Saskia, et al.
Publicado: (2020)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Corrigendum to: Edoxaban in AF patients with PCI by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
Publicado: (2020)

In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin
por: Alroomi, Moudhi, et al.
Publicado: (2022)

Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry
por: Dong, Zhimin, et al.
Publicado: (2022)

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study
por: Scheres, LJJ, et al.
Publicado: (2018)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
por: Baldus, Stephan, et al.
Publicado: (2023)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Multivariate model for cooperation: bridging social physiological compliance and hyperscanning
por: Sciaraffa, Nicolina, et al.
Publicado: (2020)

Crack detection for concrete bridges with imaged based deep learning
por: Wan, Chunfeng, et al.
Publicado: (2022)

Failure analysis of anchorage of cable-stayed bridge with internal defects
por: Kryvko, Andriy, et al.
Publicado: (2021)

Comparison of VTE risk scores in guidelines for VTE diagnosis in nonsurgical hospitalized patients with suspected VTE
por: Xiong, Wei, et al.
Publicado: (2023)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
por: Fanola, Christina L., et al.
Publicado: (2018)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9gk9k9jee0qe67c4a47h7989tk